Nuwellis (NASDAQ:NUWE) Cut to Sell at Wall Street Zen

Nuwellis (NASDAQ:NUWE) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday, Wall Street Zen reports.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Nuwellis in a research note on Monday, September 21st. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, Nuwellis currently has an average rating of “Sell”.

Nuwellis Trading Down 2.6%

Shares of NUWE opened at $4.90 on Friday. The firm has a market cap of $2.65 million, a P/E ratio of -0.00 and a beta of 0.03. Nuwellis has a 12-month low of $2.52 and a 12-month high of $1,556.07. The company’s 50-day moving average price is $6.03 and its 200 day moving average price is $206.53.

Nuwellis (NASDAQ:NUWE) last released its quarterly earnings results on Thursday, November 12th. The company reported ($5.81) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($122.85) by $117.04. The business had revenue of $2.21 million for the quarter, compared to the consensus estimate of $2.50 million. Nuwellis had a negative net margin of 150.50% and a negative return on equity of 1,259.16%.

About Nuwellis

Nuwellis, Inc. is a medical device company focused on fluid management therapies for patients with fluid overload. The company develops and commercializes ultrafiltration technologies designed to remove excess salt and fluid from the blood when conventional diuretic therapy may be inadequate or poorly tolerated. Nuwellis’ principal product is the Aquadex system, including the Aquadex FlexFlow system, a compact ultrafiltration platform used in hospital settings. The system is intended for temporary extracorporeal fluid removal in patients with conditions such as fluid overload associated with heart failure, renal dysfunction, and other critical-care needs.